Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The Best Portable Applications for Emotional wellness and Prosperity - 2From blowouts to big interiors, ‘Tuscan Mom’ style is Gen Z’s answer to beige burnout
- 32025 Arctic League telethon raises more than $39k
- 4No more attempts to free whale stranded off Germany, officials say
- 5Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- HR exec caught on Coldplay 'kiss cam' with boss finally breaks her silence: 'I made a bad decision and had a couple of High Noons'
- $30K Disability Scam Implodes After Surf Trip in Mexico
- Venice’s newest marvel is a wild, acrobatic dolphin. His refusal to leave puts him in danger
- Extraordinary Picks for Home Apparatuses: Making Life Simpler
- Moon rocket and weather are on NASA's side for the first astronaut launch in decades
- Ten Awesome Authentic Realities That Will Leave You Interested
- From School Dropout to Example of overcoming adversity: My Excursion
- Rocket Lab launches mystery satellite for 'confidential commercial customer' (video)
- Glen Powell will host 'Saturday Night Live' with Olivia Dean as musical guest: What to know ahead of their debut
